| Specialty pharmaceutical company iX Biopharma announced that it has been granted a patent in Israel (Patent no. 238104) for its WaferiX™ drug delivery technology. The patent will expire on 11 October 2033 and will provide key intellectual property protection for the Singapore-listed company's WaferiX™ delivery technology platform in Israel. Further, iX Biopharma updated that following its announcement on 9 June 2020 that it had received a notice of allowance from the United States Patent and Trademark Office for WaferiX™（U.S. Patent Application No 13/504,309), the patent has now been issued as Patent no. 10,744,086. The patent will expire on 26 October 2030. |
Watch iX Biopharma's WaferiX video:
WaferiX™ is a multiple drug carrier platform technology that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e. placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream.
Produced via the Group’s proprietary freeze-drying technique, the porous and amorphous WaferiX™ matrix holding the active molecules is designed to collapse quickly within the sublingual space.
|
Stock price |
23 c |
|
52-week range |
13 – 35 c |
|
Market cap |
S$159 m |
|
PE (ttm) |
- |
|
Dividend yield |
- |
|
Year-to-date |
10% |
|
Shares outstanding |
693 m |
|
Source: Bloomberg |
|
The molecules can then be transported rapidly across the sublingual membrane into the blood vessels for a rapid onset of action in the body.
The technology has also been proven to increase the bioavailability of drug actives as well as predictability of effect.
With Israel’s grant of patent, iX Biopharma’s intellectual property rights for its sublingual wafer technology is now secured in 5 continents and all key markets including the United States, China, Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia, and Indonesia, countries in the European Union and others.